Condition: Perforating Artery Infarction · PAI · Sponsor: Neurodawn Pharmaceutical Co., Ltd.
The goal of this clinical trial is to learn if Y-6 sublingual tablets work to improve functional outcomes in patients with acute perforating artery infarction. It will also learn about the safety of Y-6 sublingual tablets. The main questions it aims to answer are: Does Y-6 sublingual tablets increase the proportion of participants who achieve a modified Rankin Scale (mRS) score of 0-1 at Day 90 after treatment? What medical problems do participants have when taking Y-6 sublingual tablets? Researchers will compare different doses of Y-6 sublingual tablets and placebo to evaluate the effectiveness and safety of Y-6 sublingual tablets in patients with acute perforating artery infarction. Participants will: Take Y-6 sublingual tablets or placebo according to the assigned treatment regimen. Visit the clinic for assessments of neurological function, functional outcomes, and safety during the study period. Complete clinical assessments, including neurological examinations, laboratory tests, and other safety evaluations. Be followed for functional outcomes and safety events after treatment.
This description comes directly from the study's public registry record.
Yilong Wang · 13911666571 · yilong528@aliyun.com
Always discuss trial participation with your own doctor first.
| Beijing TianTan Hospital | Beijing, Beijing Municipality, China | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07721545